Alpine Immune Sciences (ALPN)
ALPN
Immunology
BiotechSign Signal Grade
F
Signal Grade
26.9/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
42
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
2
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
1 Phase 1, 1 Phase 2, 1 Phase 3
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial. — BMJ 2026 Jul 23 PMID 42492944
- Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19. — Antimicrob Agents Chemother 2026 Aug 5 PMID 42429789
- Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. — Lancet 2026 Jun 13 PMID 42242268
- Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. — J Immunother Cancer 2026 May 8 PMID 42103356
- Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies. — Cancer 2026 May 1 PMID 42028885
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Alpine Immune Sciences.
Full ALPN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.